Terminated NA INTERVENTIONAL 1-arm NCT00772668

Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL

Pilot Study of RCVELP as First Line Therapy for Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL)

Sponsor: University of Miami

Conditions Follicular Lymphoma Lymphoma Marginal Zone Lymphoma

Interventions Bortezomib Cyclophosphamide Prednisone Rituximab

Updated 9 times since 2017 Last updated: Nov 6, 2017 Started: Sep 25, 2009 Primary completion: Dec 31, 2010 Completion: Feb 28, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Funding

This NA trial investigates Follicular Lymphoma and Lymphoma and is currently terminated or withdrawn. University of Miami leads this study, which shows 9 recorded versions since 2009 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

9 versions recorded

Jan 2026 — Present [monthly]

Terminated NA
Sep 2024 — Present [monthly]

Terminated NA
Jul 2024 — Sep 2024 [monthly]

Terminated NA
Dec 2021 — Jul 2024 [monthly]

Terminated NA
Jan 2021 — Dec 2021 [monthly]

Terminated NA

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated NA
Dec 2017 — Jun 2018 [monthly]

Terminated NA
Feb 2017 — Dec 2017 [monthly]

Terminated NA
Jan 2017 — Feb 2017 [monthly]

Terminated NA

First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Miami

Data source: University of Miami

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Miami, United States